Sanna Alessandro

10PUBLICATIONS
53CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 14, 2026
Long-Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.

|Mar 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfò

|Mar 10, 2026
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin

|Mar 04, 2026
Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy.

Francesco Autore, Andrea Visentin, Candida Vitale

|Jan 28, 2026
Fitness in CLL.

Claudia Baratè, Ilaria Scortechini, Sara Ciofini

|Dec 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Ernesto Vigna, Enrica Antonia Martino, Annalisa Pitino

Pageof 2

Frequent Collaborators

7 joint publications

Paolo Sportoletti

3 joint publications

Francesca Romana Mauro

3 joint publications

Luca Laurenti

2 joint publications

Anna Maria Frustaci